N. Azarnia

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

James A. Bonner, Paul M. Harari, J. Giralt et al. · New England Journal of Medicine · 2006 · 5.1K citations · Full text

Medicine, Oncology, Radiation Oncology +13

Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines

Heinz‐Josef Lenz, Eric Van Cutsem, Shirin Khambata‐Ford et al. · Journal of Clinical Oncology · 2006 · 537 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma

Lyndsay N. Harris, Gerald Batist, Robert J. Belt et al. · Cancer · 2001 · 511 citations · Full text

Medicine, Oncology, Pharmacology +17

A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11.

James D. Cox, N. Azarnia, Roger W. Byhardt et al. · Journal of Clinical Oncology · 1990 · 472 citations

Medicine, Oncology, Radiation Oncology +14

Phase II Multicenter Study of the Epidermal Growth Factor Receptor Antibody Cetuximab and Cisplatin for Recurrent and Refractory Squamous Cell Carcinoma of the Head and Neck

Roy S. Herbst, Matthew A. Arquette, Dong M. Shin et al. · Journal of Clinical Oncology · 2005 · 402 citations · Full text

Medicine, Oncology, Pharmacotherapy +16